| New Threats to U.S. Blood Supply Blood banks have added a number of new tests on donated blood in recent years, including checks for West Nile virus. But screening tests don't exist for many new infectious threats. online.wsj.com |
Genoptix Provides First Look at Second Quarter Results and Updates 2010 Guidance (PR Newswire) Genoptix, Inc. , a specialized laboratory services provider, today provided a first look at performance for the second quarter of 2010 and announced an update to annual guidance expectations for full-year 2010.  us.rd.yahoo.com |
Genoptix Announces Participation at 2010 Southern California Investor Conference (PR Newswire) Genoptix, Inc. , a specialized laboratory services provider, today announced the Company's participation at the Southern California Investor Conference to be held August 17, 2010 at The Island Hotel, Newport Beach, CA. us.rd.yahoo.com |
Genzyme, Sanofi May Eventually Come to Terms: Focus on Biotech Deals The Burrill Report submits: By Marie DaghlianSanofi-Aventis (SNY) made a formal offer to acquire Genzyme (GENZ) for $69 per share, an offer that was unanimously rejected by Genzyme’s board of directors as unrealistic and opportunistic. Complete Story » seekingalpha.com |
GE / Clarient Deal Expected to Accelerate Development of New Cancer Diagnosis Tools M.E. Garza submits: GE Healthcare, a unit of General Electric (NYSE: GE), has agreed to a $580M deal to acquire Clarient, Inc. (NASDAQ: CLRT), a leading molecular diagnostics firm. GE's Healthcare unit will pay $5 per common Clarient share or $20 per preferred share. This doesn't come as a big surprise. Back in early August, we released a report on Clarient where we recognized them to be a long-term leader in cancer diagnostics and molecular testing. They combine innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. The rise of individualized medicine as the new direction in oncology has created a need for CLRT's resources in leading diagnostic technologies, such as flow cytometry and molecular testing. GE must be very interested in some of CLRT's next generation tests like Mammostrat and their proprietary taxane predictive product line that includes an array of tests created for lung, ovarian and breast cancers, among others. This represents more than a 50% gain from our initial coverage.Complete Story » seekingalpha.com |